Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Anemia 7Neoplasms 3Multiple Myeloma 3Leukemia 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms, Plasma Cell 2Myelodysplastic Syndromes 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Peripheral Nervous System Diseases 1Neoplasm Metastasis 1Mycosis Fungoides 1Motor Activity 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Prolymphocytic 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Glutamine 3Physical Therapy Modalities 2Acupuncture Therapy 2glutamic acid diethyl ester 1Thioctic Acid 1Sugars 1Pain Management 1N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid 1Minocycline 1Low-Level Light Therapy 1Ketamine 1Glutamic Acid 1Exercise 1Epoetin Alfa 1Duloxetine Hydrochloride 1Dietary Supplements 1Biopsy 1Analgesia 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Peripheral Nervous System Diseases × Epoetin Alfa × Clear all
NCT00267007 2014-06-04

A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Terminated
32 enrolled 9 charts

Neoplasms, Peripheral Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡